Aimovig

RSS

erenumab

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Aimovig and why it is authorised in the EU

Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.

Aimovig contains the active substance erenumab.

This EPAR was last updated on 08/08/2018

Authorisation details

Product details
Name
Aimovig
Agency product number
EMEA/H/C/004447
Active substance
erenumab
International non-proprietary name (INN) or common name
erenumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02CX07
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
26/07/2018
Contact address
Vista Building Elm Park
Merrion Road
Dublin 4
Ireland

Product information

26/07/2018 Aimovig - EMEA/H/C/004447 - -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANALGESICS

Therapeutic indication

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

Assessment history

How useful was this page?

Add your rating
Average
1 rating